StreetAlpha.app
Home › Stocks › GMAB

Genmab a (GMAB)

Healthcare
$50.60
▼ −1.46%
LAST CLOSE · NOV 20

Genmab develops antibody therapies, including cancer treatments, from its base in Copenhagen, Denmark. It last closed at $50.60 on Nov 20, down 1.46% on the day.

AI Auto Pilots
Is GMAB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GMAB.

Key Stats

Last 12 months
Results
Revenue
$3.7B
+19.2% vs a year ago
Net income
$963.0M
−15.0% vs a year ago
Free cash flow
$1.1B
30.9% margin
Operating margin
28.6%
$1.1B operating income
Balance sheet
Cash & equivalents
$1.7B
At Dec 31
Debt
$5.3B
At Dec 31
Shareholder equity
$5.8B
ExchangeNasdaq
Financials history
FY2023: $2.4B$2.4BFY2023FY2024: $3.1B$3.1BFY2024FY2025: $3.7B$3.7BFY2025

From GMAB's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 17). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on file yet
Reported EPS
—
Quarter ended Jun 2025
Year ago EPS
—
Same quarter last year
Revenue
$925.0M
+18.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Jun 2024: $779.0MJun '24Jun 2025: $925.0MJun '25Latest $925.0M
StreetAlpha's call on GMABStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on GMAB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on GMAB

Technical Analysis

GMAB · as of the Nov 20 close · updated each morning
Uptrend

The stock sits between its 20 and 50 day averages. It is 37% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 55). The nearest support is the Pivot S1 at $49.99, and the nearest resistance the Pivot at $50.85.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 4.0%/day
Key levels
$59.9752 week high+18.5%
$59.97Swing high (Oct 28)+18.5%
$52.7720 day average+4.3%
$51.47Pivot R1+1.7%
$50.85Pivot+0.5%
$50.60Last close
$49.99Pivot S1−1.2%
$42.9850 day average−15.1%
$36.94100 day average−27.0%
$36.12Swing low (Oct 14)−28.6%
$32.01200 day average−36.7%
$23.6252 week low−53.3%
Indicators
RSI (14)55.23Middle of its rangeNeutral
MACD2.37Below its signal lineBearish
Stochastic6.7Near the bottom of its rangeOversold
ADX (14)39.9Trending up
Williams %R-94.3Oversold below −80, overbought above −20Oversold
CCI (20)-50.5Oversold below −100, overbought above 100Neutral
Rate of change−5.7%Change over 10 sessionsBearish
ATR (14)$2.03Typical daily range, 4.0% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for GMAB

What happened before

See how GMAB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow GMAB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How GMAB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for GMABHow many large options trades hit GMAB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

GMAB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲193 buying vs 122 selling
  • ▲Shares held by funds +30.8%
  • ▲Funds holding +40
  • ▼Superinvestors: 1 added, 3 cut
  • ▼Put/call 0.01 to 0.15
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding333293+13.7%
In funds' top 1075+40.0%
Held by funds–––
New / increased75 / 11846 / 100+32.2%
Reduced / sold out87 / 35102 / 32−9.0%
Put/call ratio0.150.01+1668.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GMAB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GMAB is in one of them and how their past GMAB trades turned out.

GMAB in the AI portfolios
Loading…

GMAB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GMAB in an article yet. Here's the latest on the wider market.

GMAB in the news

GMAB Congress Trades

All congress trades →
Trades, 12 months
1
Buys
1
100%
Sells
0
0%
People
1
Last filed Jul 21
Who traded GMAB · since 2020
Latest 5 filings of 13
$1K – $15KTraded Mar 30, 2026Filed Jul 21, 2026
$1K – $15KTraded Jan 16, 2025Filed Feb 10, 2025
$1K – $15KTraded Dec 16, 2024Filed Jan 14, 2025
$1K – $15KTraded Jul 19, 2024Filed Aug 15, 2024
$1K – $15KTraded Jun 18, 2024Filed Jul 9, 2024
PersonTypeAmountTradedFiledDelay
Alan ArmstrongR · OKBuy$1K – $15KMar 30, 2026Jul 21, 2026113 d
Josh GottheimerD · NJBuy$1K – $15KJan 16, 2025Feb 10, 202525 d
Josh GottheimerD · NJSell$1K – $15KDec 16, 2024Jan 14, 202529 d
Josh GottheimerD · NJBuy$1K – $15KJul 19, 2024Aug 15, 202427 d
Josh GottheimerD · NJSell$1K – $15KJun 18, 2024Jul 9, 202421 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Genmab a

Genmab is a biopharmaceutical company based in Copenhagen, Denmark. It develops antibody therapies, including treatments for cancer, and sells some products of its own while also working with collaboration partners who commercialize certain products. The company also uses data science and artificial intelligence to help find new drug targets and biomarkers.

Headquarters
1253 Copenhagen K, Denmark